Can a pill calm the immune attack in MS? a trial looks inside the spinal fluid

NCT ID NCT03963375

Completed Disease control Sponsor: Gregory Wu Source: ClinicalTrials.gov ↗

First seen Jul 28, 2026 · Last updated Jul 29, 2026 · Updated 1 time

Summary

This trial tests whether cladribine tablets change key immune cells and nerve damage markers in the spinal fluid of people with relapsing forms of multiple sclerosis. Participants take cladribine as prescribed and undergo up to two lumbar punctures to measure these biomarkers over two years. The goal is to better understand how the drug works inside the central nervous system.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cladribine tablets
What this could lead to: If it works, this could clarify how cladribine calms the immune attack on the brain and spinal cord in multiple sclerosis.
What could go wrong: This is a small, early-phase biomarker study, not designed to prove clinical benefit. The results may not translate into better outcomes for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACTIVE SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

multiple sclerosis relapsing-remitting multiple sclerosis secondary progressive multiple sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE SCLEROSIS MULTIPLE SCLEROSIS, RELAPSING-REMITTING

Contacts and locations

Locations

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226, United States
Oklahoma Medical Research Foundation

Oklahoma City, Oklahoma, 73104, United States
University of Pennsylvania

Philadelphia, Pennsylvania, 19104, United States
University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States
Washington University School of Medicine

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.